BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 84 filers reported holding BIOXCEL THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $97,526 | +1240.2% | 38,548 | +9784.1% | 0.00% | – |
| Q1 2023 | $7,277 | -98.9% | 390 | -98.7% | 0.00% | -100.0% |
| Q4 2022 | $648,868 | +913.9% | 30,208 | +524.1% | 0.00% | – |
| Q2 2022 | $64,000 | -68.8% | 4,840 | -50.5% | 0.00% | – |
| Q1 2022 | $205,000 | +141.2% | 9,785 | +135.2% | 0.00% | – |
| Q4 2021 | $85,000 | -76.5% | 4,160 | -65.2% | 0.00% | – |
| Q3 2021 | $362,000 | -8.4% | 11,941 | -12.0% | 0.00% | – |
| Q2 2021 | $395,000 | -48.8% | 13,577 | -24.0% | 0.00% | -100.0% |
| Q1 2021 | $772,000 | -12.9% | 17,876 | -6.8% | 0.00% | -50.0% |
| Q4 2020 | $886,000 | -30.1% | 19,176 | -34.4% | 0.00% | -50.0% |
| Q3 2020 | $1,268,000 | -2.6% | 29,243 | +19.0% | 0.00% | -33.3% |
| Q2 2020 | $1,302,000 | +61.9% | 24,565 | -31.7% | 0.01% | -14.3% |
| Q1 2020 | $804,000 | – | 35,982 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| APIS CAPITAL ADVISORS, LLC | 40,000 | $836,000 | 1.01% |
| ACT CAPITAL MANAGEMENT, LLC | 20,000 | $418,000 | 0.44% |
| Knoll Capital Management, LLC | 20,000 | $418,000 | 0.26% |
| Artemis Investment Management LLP | 1,428,228 | $29,855,000 | 0.24% |
| Rubric Capital Management LP | 268,528 | $5,615,000 | 0.20% |
| Virtus ETF Advisers LLC | 7,713 | $161,000 | 0.07% |
| BOOTHBAY FUND MANAGEMENT, LLC | 107,700 | $2,252,000 | 0.05% |
| PDT Partners, LLC | 28,031 | $586,000 | 0.05% |
| AllSquare Wealth Management LLC | 3,162 | $66,000 | 0.04% |
| Hennion & Walsh Asset Management, Inc. | 35,221 | $736,000 | 0.04% |